Novavax (NASDAQ:NVAX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Novavax (NASDAQ:NVAX) from a hold rating to a sell rating in a research report report published on Saturday.

A number of other equities analysts have also recently commented on NVAX. Bank of America reissued an “underperform” rating and set a $7.00 price target (down previously from $9.00) on shares of Novavax in a report on Wednesday, August 20th. HC Wainwright upped their price target on shares of Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Cantor Fitzgerald initiated coverage on Novavax in a research note on Friday, October 24th. They issued an “overweight” rating and a $18.00 price target for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research report on Wednesday, October 8th. Finally, TD Cowen lowered their target price on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Novavax presently has an average rating of “Hold” and an average target price of $10.71.

Novavax Price Performance

Shares of NASDAQ NVAX opened at $7.44 on Friday. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93. The company has a market cap of $1.21 billion, a PE ratio of 3.26, a price-to-earnings-growth ratio of 0.12 and a beta of 2.68. Novavax has a twelve month low of $5.01 and a twelve month high of $11.55. The business’s 50 day moving average price is $8.39 and its two-hundred day moving average price is $7.58.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The company had revenue of $70.45 million during the quarter, compared to analyst estimates of $55.63 million. During the same quarter last year, the company posted ($0.76) EPS. The firm’s quarterly revenue was down 16.7% on a year-over-year basis. Novavax has set its FY 2025 guidance at EPS. On average, analysts predict that Novavax will post -1.46 EPS for the current year.

Hedge Funds Weigh In On Novavax

Large investors have recently added to or reduced their stakes in the business. State of Wyoming purchased a new position in Novavax during the second quarter worth about $52,000. Signaturefd LLC lifted its position in shares of Novavax by 47.2% during the 2nd quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,122 shares in the last quarter. Vise Technologies Inc. purchased a new position in shares of Novavax in the 2nd quarter worth approximately $70,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Novavax in the first quarter valued at approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Novavax during the second quarter valued at approximately $72,000. Institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.